Long-Acting Beta Agonists Enhance Allergic Airway Disease

Knight, John; Mak, Garbo; Shaw, Joanne; McDermott, Catherine; Roberts, Luz; You, Ran; Yuan, Xiaoyi; Millien, Valentine O.; Qian, Yuping; Song, Lizhen; Vincent, Frazier; Kim, Choel; Kim, Jeong J; Bond, Richard A.; Luong, Amber U.; Kheradmand, Farrah; McMurray, John S.; Mandal, Pijus K.; Morlacchi, Pietro; Milner, Joshua D.; Corry, David B.

doi:10.1016/j.jaci.2014.12.1875

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This transcription factor is a downstream component of the Janus kinase (JAK) pathway and contributes to Th cell differentiation, Ig isotype switching, and epithelial cell activation 118 . STAT6 has been found to be up‐regulated in airways of asthmatic patients, 119,120 and transgenically engineered STAT6 ‐/‐ mice have complete absence of IL‐4/IL‐13 allergic airway responses 121,122 …”

Section: Introductionmentioning

confidence: 99%

Targetable pathogenic mechanisms in nasal polyposis

Schneider¹,

Schleimer

Tan

2021

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a challenging disease entity with significant rates of recurrence following appropriate medical and surgical therapy. Recent approval of targeted biologics in CRSwNP compels deeper understanding of underlying disease pathophysiology. Both of the approved biologics for CRSwNP modulate the type 2 inflammatory pathway, and the majority of drugs in the clinical trials pathway are similarly targeted. However, there remain multiple other pathogenic mechanisms relevant to CRSwNP for which targeted therapeutics already exist in other inflammatory diseases that have not been studied directly. In this article we summarize pathogenic mechanisms of interest in CRSwNP and discuss the results of ongoing clinical studies of targeted therapeutics in CRSwNP and other related human inflammatory diseases.

show abstract

Section: Introductionmentioning

confidence: 99%